Efficacy and safety of basiliximab in kidney transplantation.

about

Efficacy and safety of basiliximab in kidney transplantation.

Item

http://www.wikidata.org/entity/Q36150553

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Efficacy and safety of basiliximab in kidney transplantation.

@ast

Efficacy and safety of basiliximab in kidney transplantation.

@en

type

Item

label

Efficacy and safety of basiliximab in kidney transplantation.

@ast

Efficacy and safety of basiliximab in kidney transplantation.

@en

prefLabel

Efficacy and safety of basiliximab in kidney transplantation.

@ast

Efficacy and safety of basiliximab in kidney transplantation.

@en

P1476

Efficacy and safety of basiliximab in kidney transplantation

@en

P2093

Franco Mosca

http://www.w3.org/2001/XMLSchema#string

Gabriella Amorese

http://www.w3.org/2001/XMLSchema#string

Gaetano Rizzo

http://www.w3.org/2001/XMLSchema#string

Marco Del Chiaro

http://www.w3.org/2001/XMLSchema#string

Mario Del Tacca

http://www.w3.org/2001/XMLSchema#string

Massimiliano Barsotti

http://www.w3.org/2001/XMLSchema#string

Stefano Signori

http://www.w3.org/2001/XMLSchema#string

Ugo Boggi

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials.

Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy.

Signaling domains of the interleukin 2 receptor.

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.

Reducing adverse effects of immunosuppressive agents in kidney transplant recipients.

A benefit-risk assessment of basiliximab in renal transplantation.

New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis.

Uremia as a state of immune deficiency.

Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.

Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts.

P304

473-490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.4.3.473

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Piero Marchetti

Fabio Vistoli

Romano Danesi

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15934854

http://www.w3.org/2001/XMLSchema#string